MarketCap
Facebook
X
Telegram
MEDNAX Financial Ratios 2025-2007 | MD
Brief overview of MEDNAX's valuation and returns
The review covers five available annual periods spanning 2017 to 2025.
Key multiples at the end of the period are P/E 9.57x (median 15.2x), EV/EBITDA 14.42x (median 11.74x), P/S 0.83x (median 0.72x). On average, multiples differ from their five-year medians by only 0%. Valuation is near its familiar historical range.
The inverse P/E implies an earnings yield of 10.4%. This is not a dividend yield, but current earnings relative to market price.
End-period return metrics are ROE 19.1%, ROA 7.4%, ROCE 24.1%. Business quality is high on return ratios, supporting the ability to create value.
Price, earnings and growth produce a PEG of 0.27x. A value below one indicates moderate pricing relative to expected growth.
The cash conversion cycle is 46.7 days versus 51.9 days initially. Turnover changed little.
Valuation takeaway
MEDNAX's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios MEDNAX
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
9.6 | -14.3 | -11.5 | 21.5 | 15.2 | -2.6 | -1.4 | 11.9 | 15.8 | 19.6 | 19.4 | 20.5 | 19.7 | 17.7 | 16.0 | 6.3 | 5.4 | 7.3 | - |
P/S |
0.8 | 0.7 | 0.3 | 0.7 | 1.0 | 1285.4 | 0.6 | 0.9 | 1.5 | 2.0 | 2.3 | 2.7 | 2.6 | 2.4 | 2.2 | - | - | - | - |
EPS |
2.0 | -1.2 | -0.7 | 0.8 | 1.5 | -9.6 | -17.9 | 3.0 | 3.5 | 3.5 | 3.6 | 3.2 | 2.8 | 2.5 | 2.3 | 4.3 | 3.9 | 3.7 | - |
EV (Enterprise Value) |
2.59 B | 2.58 B | 1.99 B | 2.87 B | 3.43 B | 3.51 B | 4.62 B | 6 B | 7.79 B | 8.89 B | 8.57 B | 7.81 B | 6.21 B | 4.96 B | 4.01 B | 1.85 B | 1.43 B | 1.23 B | -103 M |
EBITDA per Share |
2.74 | -0.44 | 0.53 | 2.5 | 2.77 | 1.52 | 5.78 | 6.34 | 6.22 | 7.05 | 6.64 | 5.82 | 4.86 | 4.2 | 3.89 | 7.18 | 6.7 | 5.53 | - |
EV/EBITDA |
11.2 | -70.6 | 45.8 | 13.8 | 14.4 | 14.4 | 7.6 | 9.2 | 11.7 | 12.1 | 12.4 | 12.6 | 11.2 | 10.5 | 9.3 | 5.5 | 4.7 | 4.8 | - |
PEG |
-0.05 | 0.27 | 0.65 | -13.34 | -7.52 | 0.15 | 0.0 | -1.13 | -11.26 | -5.82 | 2.25 | 1.07 | 1.31 | 2.19 | 2.98 | - | - | - | - |
P/B |
1.8 | 1.9 | 0.8 | 1.6 | 2.2 | 2.7 | 1.4 | 1.0 | 1.6 | 2.3 | 2.7 | 2.9 | 2.4 | 2.1 | 2.0 | 0.9 | 0.8 | - | - |
P/CF |
5.8 | 6.9 | 5.0 | 8.5 | 25.9 | 10.0 | 6.6 | 13.2 | 10.9 | 15.7 | 19.1 | 16.1 | 14.2 | 13.7 | 14.5 | 5.3 | 3.9 | 6.9 | - |
ROE % |
19.10 | -12.95 | -7.11 | 7.44 | 14.61 | -106.52 | -99.91 | 8.70 | 10.45 | 11.77 | 13.80 | 14.01 | 11.97 | 11.84 | 12.59 | 14.00 | 14.77 | 17.53 | - |
ROA % |
7.36 | -4.60 | -2.72 | 2.83 | 4.81 | -23.79 | -36.12 | 4.53 | 5.46 | 6.09 | 7.40 | 8.79 | 9.20 | 8.76 | 9.59 | 9.95 | 10.41 | - | - |
ROCE % |
24.12 | -8.98 | 0.86 | 19.37 | 22.63 | 13.12 | 11.33 | 8.20 | 9.00 | 11.69 | 13.55 | 16.07 | 16.61 | 15.69 | 17.61 | 21.62 | 24.28 | 25.08 | - |
Current Ratio |
1.6 | 1.6 | 1.6 | 1.6 | 1.5 | 1.3 | 1.4 | 1.3 | 1.2 | 1.3 | 1.2 | 1.1 | 1.3 | 1.3 | 1.3 | 3.5 | 3.4 | - | - |
DSO |
46.7 | 48.3 | 52.1 | 55.4 | 51.9 | 85297.2 | 51.8 | 54.3 | 53.2 | 56.8 | 58.4 | 52.7 | 48.4 | 49.8 | 52.9 | - | - | - | - |
DPO |
- | - | - | - | - | - | 5.5 | 4.3 | 5.1 | 4.8 | 4.3 | 7.3 | 4.7 | 4.2 | 4.3 | 2.0 | - | - | - |
Operating Cycle |
46.7 | 48.3 | 52.1 | 55.4 | 51.9 | 85297.2 | 51.8 | 54.3 | 53.2 | 56.8 | 58.4 | 52.7 | 48.4 | 49.8 | 52.9 | - | - | - | - |
Cash Conversion Cycle |
46.7 | 48.3 | 52.1 | 55.4 | 51.9 | 85297.2 | 46.3 | 50.0 | 48.1 | 52.0 | 54.1 | 45.4 | 43.7 | 45.7 | 48.6 | -2.0 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios MEDNAX
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.5 | 0.37 | - | 0.85 | 0.46 | 0.25 | - | 0.23 | -1.84 | 0.05 | - | 0.26 | 0.34 | 0.17 | - | 0.37 | 0.32 | -0.25 | - | 0.36 | 0.41 | 0.21 | -0.76 | -0.49 | -8.06 | -0.22 | 0.11 | -15.23 | -0.1 | -2.82 | 0.68 | 0.72 | 0.85 | 0.68 | 1.47 | 0.71 | 0.69 | 0.59 | 0.84 | 1.04 | 0.89 | 0.74 | 1 | 0.98 | 0.91 | 0.73 | 0.9 | 0.87 | 0.8 | 0.64 | 0.79 | 0.77 | 0.7 | 0.56 | 0.67 | 0.67 | 0.62 | 1 | 1.21 | 1.21 | 1.18 | 0.96 | 1.31 | 1.06 |
EBITDA per Share |
0.79 | 0.59 | - | 0.87 | 0.77 | 0.44 | - | 0.48 | -1.79 | 0.32 | - | 0.6 | 0.7 | 0.48 | - | 0.69 | 0.69 | 0.56 | - | 0.79 | 0.68 | 0.4 | 0.47 | 0.33 | 0.49 | 0.21 | 0.57 | 0.67 | 0.59 | 0.54 | 1.45 | 1.39 | 1.53 | 1.29 | 1.64 | 1.64 | 1.6 | 1.43 | 1.81 | 1.96 | 1.82 | 1.56 | 1.82 | 1.81 | 1.69 | 1.36 | 1.58 | 1.51 | 1.42 | 1.16 | 1.35 | 1.34 | 1.24 | 1.02 | 1.13 | 1.18 | 1.11 | 1.79 | 2.05 | 2.11 | 2.09 | 1.73 | 1.87 | 1.87 |
ROE % |
20.65 | 18.75 | 15.39 | 18.04 | -11.67 | -15.91 | -18.54 | -16.33 | -15.98 | 7.24 | 6.77 | 10.35 | 11.35 | 5.93 | 4.37 | 8.01 | 8.76 | 7.85 | 10.27 | 1.67 | -7.47 | -101.75 | -106.56 | -97.33 | -175.62 | -86.21 | -99.91 | -98.59 | -12.68 | -9.56 | 8.70 | 11.19 | 11.21 | 10.72 | 10.45 | 8.84 | 10.18 | 11.09 | 11.77 | 12.74 | 12.97 | 13.44 | 13.80 | 13.90 | 13.98 | 14.02 | 14.01 | 13.48 | 12.96 | 12.42 | 11.97 | 11.85 | 11.80 | 11.82 | 11.84 | 11.96 | 12.09 | 12.34 | 12.59 | 13.68 | 14.11 | 2.63 | 4.46 | 3.80 |
ROA % |
8.43 | 7.60 | 6.17 | 7.10 | -3.83 | -5.51 | -6.55 | -5.63 | -5.34 | 2.94 | 2.76 | 4.08 | 2.25 | 2.19 | 1.58 | 2.95 | 1.63 | 2.34 | 3.24 | 1.32 | -1.07 | -22.52 | -23.79 | -21.64 | -50.71 | -30.83 | -36.12 | -35.34 | -3.94 | -2.40 | 4.52 | 5.83 | 5.85 | 5.60 | 5.46 | 4.60 | 5.29 | 5.75 | 6.09 | 6.66 | 6.85 | 7.16 | 7.40 | 7.81 | 8.20 | 8.54 | 8.79 | 8.97 | 9.14 | 9.25 | 9.32 | 9.10 | 8.94 | 8.84 | 8.76 | 8.92 | 9.09 | 9.35 | 9.59 | 10.43 | 10.67 | 2.00 | 3.40 | 2.80 |
ROCE % |
26.02 | 23.63 | 18.89 | 23.51 | -6.46 | -11.78 | -15.85 | -11.69 | -11.16 | 14.46 | 12.61 | 18.13 | 19.90 | 19.21 | 15.91 | 22.86 | 23.53 | 21.00 | 16.54 | 20.86 | 16.64 | 15.09 | 13.13 | 11.48 | 11.99 | 10.24 | 11.46 | 12.20 | 12.33 | 13.42 | 13.98 | 14.67 | 15.41 | 15.43 | 15.66 | 16.73 | 18.29 | 19.67 | 20.71 | 21.73 | 22.25 | 22.68 | 22.89 | 22.92 | 22.82 | 22.77 | 22.65 | 21.71 | 20.87 | 19.99 | 19.30 | 19.07 | 19.08 | 19.14 | 19.14 | 19.36 | 19.58 | 20.06 | 20.53 | 21.17 | 21.99 | 4.37 | 5.93 | 6.31 |
Current Ratio |
1.7 | 1.7 | 1.6 | 1.7 | 1.7 | 1.7 | 1.6 | 1.5 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | - | 1.6 | 1.5 | 1.5 | 1.5 | 1.4 | 1.3 | 1.3 | 1.3 | 1.3 | 1.6 | 1.6 | 1.6 | 1.6 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.2 | 2.2 | 2.2 | 2.2 | 2.7 | 2.7 | 2.7 | 2.7 | 4.5 | 4.5 | 4.5 | 4.5 | 3.9 | 3.9 | 3.9 | 3.9 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 | 3.8 |
DSO |
42.3 | 43.5 | - | 43.5 | 46.9 | 50.0 | - | 50.1 | 50.5 | 51.2 | - | 49.4 | 50.1 | 53.5 | - | 27.4 | 29.8 | 58.6 | - | 42309.1 | 39045.4 | 44949.1 | 43802.0 | 78284.4 | 72381.0 | 62452.4 | 76647.5 | 54165.8 | 90500.6 | 98879.6 | 20306.8 | 26182.6 | 36784.8 | 30238.8 | -156428.3 | -191624.6 | 66748.8 | 57204.4 | 56071.9 | 56776.3 | 57280.0 | 54015.2 | 52229.4 | 51763.1 | 54472.8 | 44287.3 | 35511.0 | 44327.5 | 214249.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.0 | 7.4 | 7.6 | 8.0 | 6.3 | 4.8 | 4.9 | 5.1 | 4.5 | 4.3 | 4.3 | 4.6 | 4.4 | 4.6 | 4.5 | 4.8 | 2.3 | - | - |
Operating Cycle |
- | 43.5 | - | 43.5 | 46.9 | 50.0 | - | 50.1 | 50.5 | 51.2 | - | 49.4 | 50.1 | 53.5 | - | 27.4 | 29.8 | 58.6 | - | 42309.1 | 39045.4 | 44949.1 | 43802.0 | 78284.4 | 72381.0 | 62452.4 | 76647.5 | 54165.8 | 90500.6 | 98879.6 | 20306.8 | 26182.6 | 36784.8 | 30238.8 | -156428.3 | -191624.6 | 66748.8 | 57204.4 | 56071.9 | 56776.3 | 57280.0 | 54015.2 | 52229.4 | 51763.1 | 54472.8 | 44287.3 | 35511.0 | 44327.5 | 214249.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 43.5 | - | 43.5 | 46.9 | 50.0 | - | 50.1 | 50.5 | 51.2 | - | 49.4 | 50.1 | 53.5 | - | 27.4 | 29.8 | 58.6 | - | 42309.1 | 39045.4 | 44949.1 | 43802.0 | 78284.4 | 72381.0 | 62452.4 | 76647.5 | 54165.8 | 90500.6 | 98879.6 | 20306.8 | 26182.6 | 36784.8 | 30238.8 | -156428.3 | -191624.6 | 66748.8 | 57204.4 | 56071.9 | 56776.3 | 57280.0 | 54015.2 | 52229.4 | 51763.1 | 54472.8 | 44281.3 | 35503.6 | 44319.9 | 214241.5 | -6.3 | -4.8 | -4.9 | -5.1 | -4.5 | -4.3 | -4.3 | -4.6 | -4.4 | -4.6 | -4.5 | -4.8 | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company MEDNAX, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
China
USA
Germany
Russia
Britain
